Konrad H Stopsack
Overview
Explore the profile of Konrad H Stopsack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitchell J, Camacho N, Shea P, Stopsack K, Joseph V, Burren O, et al.
Nat Commun
. 2025 Feb;
16(1):1779.
PMID: 39971927
To assess the contribution of rare coding germline genetic variants to prostate cancer risk and severity, we perform here a meta-analysis of 37,184 prostate cancer cases and 331,329 male controls...
2.
3.
McGrath C, Shreves A, Shanahan M, Guard H, Nhliziyo M, Pernar C, et al.
Int J Cancer
. 2024 Dec;
PMID: 39663641
The most common somatic alteration in primary prostate cancer is the TMPRSS2:ERG gene fusion, which may be caused or promoted by distinct etiologic factors. The objective of this systematic review...
4.
Stopsack K, Vijai J, Conry M, Berchuck J, Kemel Y, Vasselman S, et al.
Clin Cancer Res
. 2024 Oct;
31(1):122-129.
PMID: 39450704
Purpose: Deleterious germline variants in certain DNA repair genes are risk factors for developing aggressive prostate cancer. The objective was to quantify their prognostic impact after prostate cancer diagnosis. Experimental...
5.
Su X, Stopsack K, Schmidt D, Ma D, Li Z, Scheet P, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(36):e2405543121.
PMID: 39190349
Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this...
6.
Vaselkiv J, Shui I, Grob S, Ericsson C, Giovannucci I, Peng C, et al.
Carcinogenesis
. 2024 Aug;
45(10):735-744.
PMID: 39120256
High circulating vitamin D levels and supplementation may lower prostate cancer mortality. To probe for direct effects of vitamin D signaling in the primary tumor, we assessed how activation of...
7.
Song R, Stopsack K, Ren J, Mucci L, Clinton S, Loda M, et al.
J Acad Nutr Diet
. 2024 Jul;
125(1):90-98.e5.
PMID: 38971221
Background: Higher coffee intake has been associated with reduced risk of prostate cancer, particularly aggressive forms. The activation of the phosphoinositide 3-kinase (PI3K) signaling pathway plays an important role in...
8.
Plym A, Zhang Y, Stopsack K, Ugalde-Morales E, Seibert T, Conti D, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2420034.
PMID: 38958976
Importance: Prostate cancer, a leading cause of cancer death among men, urgently requires new prevention strategies, which may involve targeting men with an underlying genetic susceptibility. Objective: To explore differences...
9.
Chen N, McGrath C, Stopsack K, Morgans A, Nethery R, Dickerman B, et al.
J Cancer Surviv
. 2024 Jul;
PMID: 38951371
Purpose: Prostate cancer survivors may benefit from a supportive social environment. We investigated associations of social integration and long-term physical and psychosocial quality of life among prostate cancer survivors who...
10.
Lenis A, Ravichandran V, Brown S, Alam S, Katims A, Truong H, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3894-3903.
PMID: 38949888
Purpose: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune...